Skip header and navigation

4 records – page 1 of 1.

Erythropoiesis-stimulating agent (ESA) therapy and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35406
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1493
Available Online
View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Anemia - drug therapy
Hematinics - therapeutic use
Subjects (LCSH)
Chronic renal failure--Complications
Hematopoietic growth factors
Renal anemia--Chemotherapy
Abstract
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1493
Less detail

VenoferĀ® iron sucrose injection

https://libcat.nshealth.ca/en/permalink/chpams35932
Nova Scotia Health Authority. Yarmouth Regional Hospital. Ambulatory Care (ABC). Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1876
Available Online
View Pamphlet
If you do not have enough iron in your blood, your red blood cells will not have enough hemoglobin. Hemoglobin carries oxygen throughout your body. When you do not have enough hemoglobin, your body may have trouble getting enough oxygen. This may cause you to feel tired or short of breath. This is called anemia. Iron sucrose (VenoferĀ®) is an injectable (given by a needle in your arm) form of iron that helps your body make hemoglobin. This pamphlet explains how to take VenoferĀ®, possible side ef…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Yarmouth Regional Hospital. Ambulatory Care (ABC)
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Iron - therapeutic use
Anemia - drug therapy
Subjects (LCSH)
Iron
Anemia
Abstract
If you do not have enough iron in your blood, your red blood cells will not have enough hemoglobin. Hemoglobin carries oxygen throughout your body. When you do not have enough hemoglobin, your body may have trouble getting enough oxygen. This may cause you to feel tired or short of breath. This is called anemia. Iron sucrose (Venofer®) is an injectable (given by a needle in your arm) form of iron that helps your body make hemoglobin. This pamphlet explains how to take Venofer®, possible side effects, and signs of an allergic reaction.
Responsibility
Prepared by: Ambulatory Care (ABC), Yarmouth Regional Hospital
Pamphlet Number
1876
Less detail

Ferrous Sulfate/Iron

https://libcat.nshealth.ca/en/permalink/chpams37242
IWK. Pharmacy. Halifax, NS: IWK Health Centre , 2019.
Pamphlet Number
PL-1206
Available Online
View Pamphlet
Ferrous Sulfate/Iron provides the body with extra iron and helps to treat/prevent anemia (low red blood cells or low hemoglobin in the blood).
Available Online
View Pamphlet
Corporate Author
IWK. Pharmacy
Place of Publication
Halifax, NS
Publisher
IWK Health Centre
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document : digital, PDF file
Subjects (MeSH)
Anemia - drug therapy
Iron - therapeutic use
Subjects (LCSH)
Amemia--Treatment
Iron in human nutrition
Abstract
Ferrous Sulfate/Iron provides the body with extra iron and helps to treat/prevent anemia (low red blood cells or low hemoglobin in the blood).
Responsibility
IWK NICU Pharmacy Team, Halifax, NS
Pamphlet Number
PL-1206
Zone
All Zones
Less detail

Erythropoieis-stimulating agents (ESAs) for chronic kidney disease (CKD) : with active cancer or a history of cancer or stroke

https://libcat.nshealth.ca/en/permalink/chpams37446
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
2217
Available Online
View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Anemia - drug therapy
Hematinics - therapeutic use
Neoplasms
Stroke
Subjects (LCSH)
Chronic renal failure--Complications
Hematopoietic growth factors
Renal anemia--Chemotherapy
Cancer
Cerebrovascular disease
Abstract
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully consider the risks and benefits of ESAs. The risks and benefits of ESAs are listed. Your health care team will talk with you about the risks and benefits of ESAs and other factors to consider when making the decision to take ESAs.
Responsibility
Prepared by: Renal Program
Pamphlet Number
2217
Less detail